STOCK TITAN

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Ardelyx (ARDX) has announced its participation in the 2024 Jefferies London Healthcare Conference. The company's leadership team, including President and CEO Michael Raab, CFO Justin Renz, and CCO Eric Foster, will engage in a fireside chat on Tuesday, November 19, 2024, at 12:30pm GMT / 7:30am EST in London.

The presentation will be accessible via live webcast on the Events and Presentations page of Ardelyx's website, with a replay available for 30 days following the event.

Ardelyx (ARDX) ha annunciato la sua partecipazione al 2024 Jefferies London Healthcare Conference. Il team di leadership dell'azienda, inclusi il Presidente e CEO Michael Raab, il CFO Justin Renz e il CCO Eric Foster, parteciperà a una chiacchierata informale martedì 19 novembre 2024, alle 12:30 GMT / 7:30 EST a Londra.

La presentazione sarà accessibile tramite webcast dal vivo nella pagina Eventi e Presentazioni del sito web di Ardelyx, con una registrazione disponibile per 30 giorni dopo l'evento.

Ardelyx (ARDX) ha anunciado su participación en la 2024 Jefferies London Healthcare Conference. El equipo de liderazgo de la empresa, incluido el presidente y CEO Michael Raab, el CFO Justin Renz y el CCO Eric Foster, participará en una charla informal el martes 19 de noviembre de 2024, a las 12:30 GMT / 7:30 EST en Londres.

La presentación será accesible a través de una transmisión por webcast en vivo en la página de Eventos y Presentaciones del sitio web de Ardelyx, con una repetición disponible durante 30 días después del evento.

Ardelyx (ARDX)2024 Jefferies London Healthcare Conference에 참여한다고 발표했습니다. 회사의 리더십 팀, 즉 CEO인 Michael Raab, CFO인 Justin Renz, CCO인 Eric Foster가 2024년 11월 19일 화요일 GMT 오후 12시 30분 / EST 오전 7시 30분에 런던에서 파이어사이드 챗에 참여할 예정입니다.

발표 내용은 Ardelyx 웹사이트의 이벤트 및 프레젠테이션 페이지에서 생중계로 접근 가능하며, 이벤트 후 30일 동안 재방송이 제공됩니다.

Ardelyx (ARDX) a annoncé sa participation à la 2024 Jefferies London Healthcare Conference. L'équipe dirigeante de l'entreprise, comprenant le Président et CEO Michael Raab, le CFO Justin Renz et le CCO Eric Foster, participera à une discussion informelle le mardi 19 novembre 2024, à 12h30 GMT / 7h30 EST à Londres.

La présentation sera accessible via un webinaire en direct sur la page Événements et Présentations du site web d'Ardelyx, avec un replay disponible pendant 30 jours après l'événement.

Ardelyx (ARDX) hat seine Teilnahme an der 2024 Jefferies London Healthcare Conference angekündigt. Das Führungsteam des Unternehmens, einschließlich Präsident und CEO Michael Raab, CFO Justin Renz und CCO Eric Foster, wird am Dienstag, den 19. November 2024, um 12:30 GMT / 7:30 EST in London an einem informellen Gespräch teilnehmen.

Die Präsentation wird über einen Live-Webcast auf der Seite Veranstaltungen und Präsentationen der Ardelyx-Website zugänglich sein, mit einer Wiedergabe, die 30 Tage nach der Veranstaltung verfügbar ist.

Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations Officer and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:30pm GMT / 7:30am EST in London.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.

About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com


FAQ

When is Ardelyx (ARDX) presenting at the 2024 Jefferies London Healthcare Conference?

Ardelyx (ARDX) will present on Tuesday, November 19, 2024, at 12:30pm GMT / 7:30am EST in London.

Which Ardelyx (ARDX) executives are participating in the 2024 Jefferies Conference?

Michael Raab (President and CEO), Justin Renz (CFO), and Eric Foster (CCO) will participate in the fireside chat.

How can investors access Ardelyx's (ARDX) presentation at the Jefferies Conference?

Investors can access the live webcast through Ardelyx's website at their Events and Presentations page. A replay will be available for 30 days after the event.

Ardelyx, Inc.

NASDAQ:ARDX

ARDX Rankings

ARDX Latest News

ARDX Stock Data

1.14B
236.85M
1.6%
62.32%
9.72%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FREMONT